Startups
Enterprise Therapeutics
Develops small molecule medicines for respiratory diseases, including cystic fibrosis. Its ion-channel therapies aim to hydrate airway mucus and improve clearance; inhaled ENaC blocker ETD001 is in clinical development.
Team
 Alex MaywegInvestor Director |
Amit MunshiChairman |
Annabella AmatulliHead of Regulatory |
Bart DzikowskiInvestor Director, NVF |
Christopher GossScientific Advisor |
 Craig RichardsonInvestor Director |
Eddie FrenchHead of CMC |
Edward McKoneScientific Advisor |
Geert-Jan MulderInvestor Director |
Henry DanahayHead of Biology |
James D. ChalmersScientific Advisor |
Jane DaviesScientific Advisor |
Janet HammondNon-Executive Director |
Joanne WagstaffHead of Finance |
John FordChief Executive Officer |
Kathy WoodwardClinical Project Manager |
Luis GaliettaScientific Advisor |
Marcus A. MallScientific Advisor |
Martin GoslingChief Scientific Officer |
Peter FinanInvestor Director |
Phil BoydChief Financial Officer |
Renu GuptaChief Medical Officer |
Richard C BoucherScientific Advisor |
Rob WoodmanInvestor Director |
Scott DonaldsonScientific Advisor |
Sherry Armstrong-WilkinsonHead of Quality and Clinical |
 Simon WardScientific Advisor |
Stephen CollingwoodHead of Chemistry |
Tony De SoyzaScientific Advisor |
Wisia WedzichaScientific Advisor |